101
|
Xing J, Deng L, Xie C, Xiao L, Zhai Y, Jin F, Li Y, Dong A. Methoxy poly(ethylene glycol)-b
-poly(octadecanoic anhydride)-b
-methoxy poly(ethylene glycol) amphiphilic triblock copolymer nanoparticles as delivery vehicles for paclitaxel. POLYM ADVAN TECHNOL 2011. [DOI: 10.1002/pat.1563] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
102
|
Luo B, Xu S, Luo A, Wang WR, Wang SL, Guo J, Lin Y, Zhao DY, Wang CC. Mesoporous biocompatible and acid-degradable magnetic colloidal nanocrystal clusters with sustainable stability and high hydrophobic drug loading capacity. ACS NANO 2011; 5:1428-1435. [PMID: 21284377 DOI: 10.1021/nn103213y] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Fabrication of magnetic particles (MPs) with high magnetization and large surface area simultaneously is critical for the application of MPs in bioseparation and drug delivery but remains a challenge. In this article, we describe an unprecedented approach to synthesize mesoporous magnetic colloidal nanocrystal clusters (MCNCs) stabilized by poly(γ-glutamic acid) (PGA) with high magnetization, large surface area (136 m(2)/g) and pore volume (0.57 cm(3)/g), excellent colloidal stability, prominent biocompatibility, and acid degradability. This result provides the important step toward the construction of a new family of MCNCs and demonstrates its capacity in a "magnetic motor" drug delivery system. Here, as an example, we explore the applicability of as-prepared mesoporous MCNCs as hydrophobic drug delivery vehicles (paclitaxel as model drug), and the resultant loading capacity is as high as 35.0 wt %. The antitumor efficacy measured by MTT assay is significantly enhanced, compared with free drugs. Thus, combined with their inherent high magnetization, the mesoporous MCNCs pave the way for applying magnetic targeting drug carriers in antitumor therapeutics.
Collapse
Affiliation(s)
- Bin Luo
- Key Laboratory of Molecular Engineering of Polymers (Minister of Education), Department of Macromolecular Science, Laboratory of Advanced Materials, Fudan University, Shanghai 200433, People's Republic of China
| | | | | | | | | | | | | | | | | |
Collapse
|
103
|
Ahmed S, Mathews AS, Byeon N, Lavasanifar A, Kaur K. Peptide arrays for screening cancer specific peptides. Anal Chem 2011; 82:7533-41. [PMID: 20799711 DOI: 10.1021/ac1003085] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
In this paper, we describe a novel method to screen peptides for specific recognition by cancer cells. Seventy peptides were synthesized on a cellulose membrane in an array format, and a direct method to study the peptide-whole cell interaction was developed. The relative binding affinity of the cells for different peptides with respect to a lead 12-mer p160 peptide, identified by phage display, was evaluated using the CyQUANT fluorescence of the bound cells. Screening allowed identification of at least five new peptides that displayed higher affinity (up to 3-fold) for MDA-MB-435 and MCF-7 human cancer cells compared to the p160 peptide. These peptides showed very little binding to the control (noncancerous) human umbilical vein endothelial cells (HUVECs). Three of these peptides were synthesized separately and labeled with fluorescein isothiocyanate (FITC) to study their uptake and interaction with the cancer and control cells using confocal laser scanning microscopy and flow cytometry. The results confirmed the high and specific affinity of an 11-mer peptide 11 (RGDPAYQGRFL) and a 10-mer peptide 18 (WXEAAYQRFL) for the cancer cells versus HUVECs. Peptide 11 binds different receptors on target cancer cells as its sequence contains multiple recognition motifs, whereas peptide 18 binds mainly to the putative p160 receptor. The peptide array-whole cell binding assay reported here is a complementary method to phage display for further screening and optimization of cancer targeting peptides for cancer therapy and diagnosis.
Collapse
Affiliation(s)
- Sahar Ahmed
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2N8, Canada
| | | | | | | | | |
Collapse
|
104
|
Hwang JH, Takagi M, Murakami H, Sekido Y, Shin-ya K. Induction of tubulin polymerization and apoptosis in malignant mesothelioma cells by a new compound JBIR-23. Cancer Lett 2011; 300:189-96. [DOI: 10.1016/j.canlet.2010.10.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2010] [Revised: 10/08/2010] [Accepted: 10/11/2010] [Indexed: 02/09/2023]
|
105
|
Blencowe CA, Russell AT, Greco F, Hayes W, Thornthwaite DW. Self-immolative linkers in polymeric delivery systems. Polym Chem 2011. [DOI: 10.1039/c0py00324g] [Citation(s) in RCA: 120] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
106
|
Jin J, Lee WS, Joo KM, Maiti KK, Biswas G, Kim W, Kim KT, Lee SJ, Kim KH, Nam DH, Chung SK. Preparation of blood-brain barrier-permeable paclitaxel-carrier conjugate and its chemotherapeutic activity in the mouse glioblastoma model. MEDCHEMCOMM 2011. [DOI: 10.1039/c0md00235f] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
107
|
Dosio F, Stella B, Arpicco S, Cattel L. Macromolecules as taxane delivery systems. Expert Opin Drug Deliv 2010; 8:33-55. [DOI: 10.1517/17425247.2011.541437] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
108
|
Dicko A, Mayer LD, Tardi PG. Use of nanoscale delivery systems to maintain synergistic drug ratiosin vivo. Expert Opin Drug Deliv 2010; 7:1329-41. [DOI: 10.1517/17425247.2010.538678] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
109
|
Zhao D, Zhao X, Zu Y, Li J, Zhang Y, Jiang R, Zhang Z. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine 2010; 5:669-77. [PMID: 20957218 PMCID: PMC2948946 DOI: 10.2147/ijn.s12918] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2010] [Indexed: 11/23/2022] Open
Abstract
Paclitaxel (Taxol®) is an important anticancer drug in clinical use for treatment of a variety of cancers. Because of its low solubility, it is formulated in high concentration in Cremophor EL® which induces hypersensitivity reactions. In this study, targeted delivery of paclitaxel-loaded nanoparticles was prepared by a desolvation procedure, crosslinked on the wall material of bovine serum albumin, and subsequently decorated by folic acid. The characteristics of the nanoparticles, such as amount of folate conjugation, surface morphology, drug entrapment efficiency, drug loading efficiency, and release kinetics were investigated in vitro. The targeting effect was investigated in vitro by cancer cell uptake of fluorescein isothiocyanate-labeled nanoparticles. The spherical nanoparticles obtained were negatively charged with a zeta potential of about −30 mV, and characterized around 210 nm with a narrow size distribution. Drug entrapment efficiency and drug loading efficiency were approximately 95.3% and 27.2%, respectively. The amount of folate conjugation was 9.22 μg/mg of bovine serum albumin. The folate-decorated nanoparticles targeted a human prostate cancer cell line effectively.
Collapse
Affiliation(s)
- Dongmei Zhao
- Key Laboratory of Forest Plant Ecology, Northeast Forestry University, Ministry of Education, Harbin, Heilongjiang, China
| | | | | | | | | | | | | |
Collapse
|
110
|
Yamazaki Y, Sumikura M, Hidaka K, Yasui H, Kiso Y, Yakushiji F, Hayashi Y. Anti-microtubule 'plinabulin' chemical probe KPU-244-B3 labeled both alpha- and beta-tubulin. Bioorg Med Chem 2010; 18:3169-74. [PMID: 20395148 DOI: 10.1016/j.bmc.2010.03.037] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2010] [Revised: 03/13/2010] [Accepted: 03/16/2010] [Indexed: 02/08/2023]
Abstract
Plinabulin (1, NPI-2358), a potent microtubule-targeting agent derived from the natural diketopiperazine 'phenylahistin' with a colchicine-like tubulin depolymerization activity, is an anticancer agent undergoing Phase II clinical trials in four countries including the United States. In order to understand the precise binding mode of plinabulin with tubulin, a new bioactive biotin-tagged photoaffinity probe 4 (KPU-244-B3) was designed and synthesized. Probe 4 showed significant binding affinity to tubulin in a binding assay, and selectively bound to tubulin in an HT-1080 cell lysate without photo-irradiation. In a tubulin photoaffinity labeling study, probe 4 labeled both alpha- and beta-tubulin subunits and these interactions were competitively inhibited by plinabulin during photo-irradiation. These results suggest that plinabulin binds in the boundary region between alpha- and beta-tubulin near the colchicine binding site, and not inside the colchicine binding cavity.
Collapse
Affiliation(s)
- Yuri Yamazaki
- Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan
| | | | | | | | | | | | | |
Collapse
|
111
|
Lay CL, Liu HQ, Tan HR, Liu Y. Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graft-carbon nanotubes for potent cancer therapeutics. NANOTECHNOLOGY 2010; 21:065101. [PMID: 20057024 DOI: 10.1088/0957-4484/21/6/065101] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
UNLABELLED Physically loading of paclitaxel (PTX) onto carbon nanotubes (CNTs) is achieved through immersion of poly(ethylene glycol) (PEG)-graft-single walled CNTs (PEG-g-SWNTs) or PEG-graft-multi-walled CNTs (PEG-g-MWNTs) in a saturated solution of PTX in methanol. After loading once the loading capacity (LD%) is 26% (w/w) and 36% (w/w) for PEG-g-SWNTs or PEG-g-MWNTs, respectively. With these PTX contents, PTX loaded PEG-g-SWNTs and PTX loaded PEG-g-MWNTs still have good dispersity in aqueous solution and individual CNTs can be observed in TEM images. PTX can be released from PEG-g-CNTs several times faster than from free PTX but still in a sustained profile with less than 40% of PTX being released in 40 days at pH 7 or 5. In vitro cytotoxicity of samples is evaluated in HeLa cells and MCF-7 cells. PEG-g-SWNTs and PEG-g-MWNTs show low cytotoxicity in both cells with insignificant effects on the cell proliferation rates. However, both PTX loaded PEG-g-SWNTs and PTX loaded PEG-g-MWNTs show high efficacy to kill HeLa cells and MCF-7 cells, as reflected by IC(50) lower than free PTX. Therefore, PTX loaded PEG-g-CNTs are promising for cancer therapeutics. KEYWORDS carbon nanotubes, poly(ethylene glycol), drug delivery, cancer therapy, nanomedicine.
Collapse
Affiliation(s)
- Chee Leng Lay
- Institute of Materials Research and Engineering, A*STAR (Agency for Science, Technology and Research), 3 Research Link, Singapore
| | | | | | | |
Collapse
|
112
|
Shahin M, Lavasanifar A. Novel self-associating poly(ethylene oxide)-b-poly(epsilon-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery. Int J Pharm 2010; 389:213-22. [PMID: 20080163 DOI: 10.1016/j.ijpharm.2010.01.015] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2009] [Revised: 12/24/2009] [Accepted: 01/10/2010] [Indexed: 12/25/2022]
Abstract
Poly(ethylene oxide)-block-poly(epsilon-caprolactone) (PEO-b-PCL) copolymers bearing paclitaxel (PTX) side groups on PCL (PEO-b-P(CL-PTX) were synthesized and assembled to particles of 123 nm average diameter. At 20% (w/w) PTX to polymer conjugation, PEO-b-P(CL-PTX) demonstrated only 5.0 and 6.7% PTX release after 72 h incubation at pH 7.4 and 5.0, respectively, but revealed signs of chain cleavage at pH 5.0. The cytotoxicity of PEO-b-P(CL-PTX) against MDA-MB-435 cancer cells increased as incubation time was raised from 72 to 96 h (IC(50) of 680 and 475 ng/mL, respectively), but it was still significantly lower than the cytotoxicity of free PTX (IC(50) of 3.5 ng/mL at 72 h). In further studies, micelles of PEO-b-PCL and those bearing benzyl or PTX on PCL were used for physical encapsulation of PTX, where maximum level of loading was achieved by PEO-b-P(CL-PTX) (2.22%, w/w). The release of PTX from this carrier was rapid; however. The in vitro cytotoxicity of physically loaded PTX was independent of carrier and similar to that of free PTX. This was attributed to the low concentration of polymers which fell below their critical micellar concentration in the cytotoxicity study. The results point to the potential of chemically tailored PEO-b-PCL for optimum PTX solubilization and delivery.
Collapse
Affiliation(s)
- Mostafa Shahin
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2N8, Canada
| | | |
Collapse
|
113
|
Tanino T, Nawa A, Nakao M, Noda M, Fujiwara S, Iwaki M. Organic anion transporting polypeptide 2-mediated uptake of paclitaxel and 2′-ethylcarbonate-linked paclitaxel in freshly isolated rat hepatocytes. J Pharm Pharmacol 2010. [DOI: 10.1211/jpp.61.08.0006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Abstract
Objectives
The P-glycoprotein (P-gp) efflux pump plays an important role in paclitaxel detoxification. However, hepatic uptake of paclitaxel mediated by a solute-linked carrier transporter family is still poorly understood in animals and humans. Freshly isolated hepatocyte suspensions are a well established in-vitro model for studying drug transport and xenobiotic metabolism. Therefore, the hepatic uptake of paclitaxel and its P-gp-insensitive prodrug, 2′-ethylcarbonate-linked paclitaxel (TAX-2′-Et), has been characterized using freshly isolated and pregnenolone-16-α-carbonitrile (PCN)-treated hepatocytes in rats.
Methods
Paclitaxel and TAX-2′-Et were incubated with rat hepatocyte suspensions in the presence or absence of inhibitors.
Key findings
Paclitaxel and TAX-2′-Et showed concentration-dependent uptake in rat hepatocytes. The intrinsic transport capacity was two-fold higher for paclitaxel uptake than for TAX-2′-Et uptake. Rifampicin (a potent inhibitor of organic anion transporting polypeptide (Oatp) 2), but not indometacin (a representative inhibitor of organic anion transporter (Oat) 2 and Oatp1) treatment, significantly inhibited the uptake of paclitaxel and TAX-2′-Et. We characterized the rifampicin-sensitive uptake of paclitaxel and TAX-2′-Et using rat hepatocytes treated with PCN, which dramatically enhances hepatic Oatp2 protein levels. PCN-treated hepatocytes displayed a 1.6-fold greater uptake of paclitaxel and TAX-2′-Et than the vehicle-treated hepatocytes. The uptake of the two compounds was significantly reduced by rifampicin but not by indometacin treatment. These findings demonstrated that the rat Oatp2, but not Oatp1 orOat2, was a candidate transporter for the hepatic uptakeofpaclitaxel and TAX-2′-Et.
Conclusions
The findings have provided an important step towards identifying a key transporter in hepatic detoxification of paclitaxel and TAX-2′-Et in small animals.
Collapse
Affiliation(s)
- Tadatoshi Tanino
- School of Pharmacy, Kinki University, Higashi-Osaka, Osaka, Japan
| | - Akihiro Nawa
- Nagoya University Graduate School of Medicine, Shouwa-ku, Nagoya, Japan
| | - Mao Nakao
- School of Pharmacy, Kinki University, Higashi-Osaka, Osaka, Japan
| | - Manabu Noda
- School of Pharmacy, Kinki University, Higashi-Osaka, Osaka, Japan
| | - Sawako Fujiwara
- Nagoya University Graduate School of Medicine, Shouwa-ku, Nagoya, Japan
| | - Masahiro Iwaki
- School of Pharmacy, Kinki University, Higashi-Osaka, Osaka, Japan
| |
Collapse
|
114
|
Ogier J, Arnauld T, Carrot G, Lhumeau A, Delbos JM, Boursier C, Loreau O, Lefoulon F, Doris E. Enhanced drug loading in polymerized micellar cargo. Org Biomol Chem 2010; 8:3902-7. [DOI: 10.1039/c004134c] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
115
|
|
116
|
Luo B, Xu S, Ma WF, Wang WR, Wang SL, Guo J, Yang WL, Hu JH, Wang CC. Fabrication of magnetite hollow porous nanocrystal shells as a drug carrier for paclitaxel. ACTA ACUST UNITED AC 2010. [DOI: 10.1039/c0jm00726a] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
117
|
Dosio F, Arpicco S, Stella B, Brusa P, Cattel L. Folate-mediated targeting of albumin conjugates of paclitaxel obtained through a heterogeneous phase system. Int J Pharm 2009; 382:117-23. [DOI: 10.1016/j.ijpharm.2009.08.018] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2009] [Revised: 08/13/2009] [Accepted: 08/16/2009] [Indexed: 10/20/2022]
|
118
|
Abstract
Anticancer prodrugs designed to target specifically tumor cells should increase therapeutic effectiveness and decrease systemic side effects in the treatment of cancer. Over the last 20 years, significant advances have been made in the development of anticancer prodrugs through the incorporation of triggers for reductive activation. Reductively activated prodrugs have been designed to target hypoxic tumor tissues, which are known to overexpress several endogenous reductive enzymes. In addition, exogenous reductive enzymes can be delivered to tumor cells through fusion with tumor-specific antibodies or overexpressed in tumor cells through gene delivery approaches. Many anticancer prodrugs have been designed to use both the endogenous and exogenous reductive enzymes for target-specific activation and these prodrugs often contain functional groups such as quinones, nitroaromatics, N-oxides, and metal complexes. Although no new agents have been approved for clinical use, several reductively activated prodrugs are in various stages of clinical trial. This review mainly focuses on the medicinal chemistry aspects of various classes of reductively activated prodrugs including design principles, structure-activity relationships, and mechanisms of activation and release of active drug molecules.
Collapse
Affiliation(s)
- Yu Chen
- Department of Pharmaceutical Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA
| | | |
Collapse
|
119
|
Lin YS, Tungpradit R, Sinchaikul S, An FM, Liu DZ, Phutrakul S, Chen ST. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters. J Med Chem 2009; 51:7428-41. [PMID: 19053781 DOI: 10.1021/jm8006257] [Citation(s) in RCA: 89] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
This report describes the synthesis of four novel paclitaxel based prodrugs with glycan conjugation (1-4). Glycans were conjugated using an ester or ether bond as the linker between 2'-paclitaxel and the 2'-glucose or glucuronic acid moiety. These prodrugs showed good water solubility and selective cytotoxicity against cancer cell lines, but showed reduced toxicity toward normal cell lines and cancer cell lines with low expression levels of GLUTs. The ester conjugated prodrug 1 showed the most cytotoxicity among the prodrugs examined and could be transported into cells via GLUTs. Fluorescent and confocal microscopy demonstrated that targeted cells exhibited morphological changes in tubulin and chromosomal alterations that were similar to those observed with paclitaxel treatment. Therefore, these glycan-based prodrugs may be good drug candidates for cancer therapy, and the glycan conjugation approach is an alternative method to enhance the targeted delivery of other drugs to cancer cells that overexpress GLUTs.
Collapse
Affiliation(s)
- Yih-Shyan Lin
- Institute of Biological Chemistry and Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan
| | | | | | | | | | | | | |
Collapse
|
120
|
Zhong W, Skwarczynski M, Toth I. Lipid Core Peptide System for Gene, Drug, and Vaccine Delivery. Aust J Chem 2009. [DOI: 10.1071/ch09149] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A vast number of biologically active compounds await efficient delivery to become therapeutic agents. Lipidation has been demonstrated to be a convenient and useful approach to improve the stability and transport across biological membranes of potential drug molecules. The lipid core peptide (LCP) system has emerged as a promising lipidation tool because of its versatile features. This review discusses the progress in the development of the LCP system to improve cell permeability of nucleotides, physicochemical properties of potential drugs, and vaccine immunogenicity. Emphasis was put on the application of the LCP system to deliver antigens for the prevention of group A streptococcus infection, novel techniques of conjugation of target molecules to the LCP, and new alterations of the LCP system itself.
Collapse
|
121
|
Yamazaki Y, Kohno K, Yasui H, Kiso Y, Akamatsu M, Nicholson B, Deyanat-Yazdi G, Neuteboom S, Potts B, Lloyd GK, Hayashi Y. Tubulin Photoaffinity Labeling with Biotin-Tagged Derivatives of Potent Diketopiperazine Antimicrotubule Agents. Chembiochem 2008; 9:3074-81. [DOI: 10.1002/cbic.200800317] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
122
|
Hwu JR, Lin YS, Josephrajan T, Hsu MH, Cheng FY, Yeh CS, Su WC, Shieh DB. Targeted Paclitaxel by Conjugation to Iron Oxide and Gold Nanoparticles. J Am Chem Soc 2008; 131:66-8. [DOI: 10.1021/ja804947u] [Citation(s) in RCA: 147] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Jih Ru Hwu
- Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan 300, R.O.C., Department of Chemistry, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., and, Department of Dentistry and Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C
| | - Yu Sern Lin
- Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan 300, R.O.C., Department of Chemistry, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., and, Department of Dentistry and Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C
| | - Thainashmuthu Josephrajan
- Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan 300, R.O.C., Department of Chemistry, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., and, Department of Dentistry and Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C
| | - Ming-Hua Hsu
- Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan 300, R.O.C., Department of Chemistry, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., and, Department of Dentistry and Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C
| | - Fong-Yu Cheng
- Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan 300, R.O.C., Department of Chemistry, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., and, Department of Dentistry and Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C
| | - Chen-Sheng Yeh
- Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan 300, R.O.C., Department of Chemistry, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., and, Department of Dentistry and Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C
| | - Wu-Chou Su
- Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan 300, R.O.C., Department of Chemistry, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., and, Department of Dentistry and Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C
| | - Dar-Bin Shieh
- Department of Chemistry, National Tsing Hua University, Hsinchu, Taiwan 300, R.O.C., Department of Chemistry, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C., and, Department of Dentistry and Institute of Oral Medicine, National Cheng Kung University, Tainan, Taiwan 701, R.O.C
| |
Collapse
|
123
|
Nguyen JT, Hamada Y, Kimura T, Kiso Y. Design of potent aspartic protease inhibitors to treat various diseases. Arch Pharm (Weinheim) 2008; 341:523-35. [PMID: 18763714 DOI: 10.1002/ardp.200700267] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
In this retrospective, personal review covering our research from the late 1980s until 2007, we outline nearly two-decade worth of our own work on several aspartic protease inhibitors including those affecting renin, HIV-1 protease, plasmepsins, beta-secretase, and HTLV-I protease and we report on aspartic protease inhibitors as potential drugs to treat hypertension, AIDS, malaria, Alzheimer's disease and adult T-cell leukemia, HTLV-I associated myelopathy / tropical spastic paraparesis, and various, respectively, associated diseases. Herein, we describe our methods for rational substrate-based drug design of peptidomimetics that potently inhibit the activity of renin, HIV-1 protease, plasmepsins, beta-secretase, and HTLV-I protease accordingly, using an appropriately selected inhibitory residue that contained a hydroxymethylcarbonyl isostere. Although this non-hydrolyzable isostere mimics the transition state that is formed during protein cleavage of a substrate, the isostere-containing inhibitor is not cleaved. We highlight our optimization studies in which we used various techniques and tools such as truncation studies, natural and non-natural amino acid substitution studies, various moieties to promote chemical and pharmacological stability, X-ray crystallography, computer-assisted docking and dynamic simulations, quantitative structure-activity relationship studies, and various other methods that this review can barely mention.
Collapse
Affiliation(s)
- Jeffrey-Tri Nguyen
- Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science and 21st Century COE Program, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto, Japan
| | | | | | | |
Collapse
|
124
|
Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc Natl Acad Sci U S A 2008; 105:12128-33. [PMID: 18713866 DOI: 10.1073/pnas.0805374105] [Citation(s) in RCA: 196] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Many cancer therapeutic agents elicit resistance that renders them ineffective and often produces cross-resistance to other drugs. One of the most common mechanisms of resistance involves P-glycoprotein (Pgp)-mediated drug efflux. To address this problem, new agents have been sought that are less prone to inducing resistance and less likely to serve as substrates for Pgp efflux. An alternative to this approach is to deliver established agents as molecular transporter conjugates into cells through a mechanism that circumvents Pgp-mediated efflux and allows for release of free drug only after cell entry. Here we report that the widely used chemotherapeutic agent Taxol, ineffective against Taxol-resistant human ovarian cancer cell lines, can be incorporated into a releasable octaarginine conjugate that is effective against the same Taxol-resistant cell lines. It is significant that the ability of the Taxol conjugates to overcome Taxol resistance is observed both in cell culture and in animal models of ovarian cancer. The generality and mechanistic basis for this effect were also explored with coelenterazine, a Pgp substrate. Although coelenterazine itself does not enter cells because of Pgp efflux, its octaarginine conjugate does so readily. This approach shows generality for overcoming the multidrug resistance elicited by small-molecule cancer chemotherapeutics and could improve the prognosis for many patients with cancer and fundamentally alter search strategies for novel therapeutic agents that are effective against resistant disease.
Collapse
|
125
|
Ansell SM, Johnstone SA, Tardi PG, Lo L, Xie S, Shu Y, Harasym TO, Harasym NL, Williams L, Bermudes D, Liboiron BD, Saad W, Prud’homme RK, Mayer LD. Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates. J Med Chem 2008; 51:3288-96. [PMID: 18465845 DOI: 10.1021/jm800002y] [Citation(s) in RCA: 103] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Steven M. Ansell
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Sharon A. Johnstone
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Paul G. Tardi
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Lily Lo
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Sherwin Xie
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Yu Shu
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Troy O. Harasym
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Natashia L. Harasym
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Laura Williams
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - David Bermudes
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Barry D. Liboiron
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Walid Saad
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Robert K. Prud’homme
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| | - Lawrence D. Mayer
- Celator Pharmaceuticals Corporation, 1779 West 75th Avenue, Vancouver, B.C., V6P 6P2, Canada, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey
| |
Collapse
|
126
|
Noguchi M, Skwarczynski M, Prakash H, Hirota S, Kimura T, Hayashi Y, Kiso Y. Development of novel water-soluble photocleavable protective group and its application for design of photoresponsive paclitaxel prodrugs. Bioorg Med Chem 2008; 16:5389-97. [DOI: 10.1016/j.bmc.2008.04.022] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2008] [Revised: 04/09/2008] [Accepted: 04/10/2008] [Indexed: 10/22/2022]
|
127
|
Leu YL, Chen CS, Wu YJ, Chern JW. Benzyl Ether-Linked Glucuronide Derivative of 10-Hydroxycamptothecin Designed for Selective Camptothecin-Based Anticancer Therapy. J Med Chem 2008; 51:1740-6. [DOI: 10.1021/jm701151c] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Yu-Ling Leu
- Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan 717, Taiwan, and School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan
| | - Chien-Shu Chen
- Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan 717, Taiwan, and School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan
| | - Yih-Jang Wu
- Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan 717, Taiwan, and School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan
| | - Ji-Wang Chern
- Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan 717, Taiwan, and School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan
| |
Collapse
|
128
|
Jiang X, Vogel EB, Smith MR, Baker GL. “Clickable” Polyglycolides: Tunable Synthons for Thermoresponsive, Degradable Polymers. Macromolecules 2008. [DOI: 10.1021/ma7027962] [Citation(s) in RCA: 160] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Xuwei Jiang
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824
| | - Erin B. Vogel
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824
| | - Milton R. Smith
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824
| | - Gregory L. Baker
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824
| |
Collapse
|
129
|
Leonelli F, La Bella A, Migneco LM, Bettolo RM. Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates. Molecules 2008; 13:360-78. [PMID: 18305424 PMCID: PMC6245481 DOI: 10.3390/molecules13020360] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2008] [Revised: 02/11/2008] [Accepted: 02/11/2008] [Indexed: 02/07/2023] Open
Abstract
Paclitaxel (1a), a well known antitumor agent adopted mainly for the treatment of breast and ovarian cancer, suffers from significant disadvantages such as low solubility, certain toxicity and specific drug-resistance of some tumor cells. To overcome these problems extensive research has been carried out. Among the various proposed strategies, the conjugation of paclitaxel (1a) to a biocompatible polymer, such as hyaluronic acid (HA, 2), has also been considered. Coupling a bioactive compound to a biocompatible polymer offers, in general, many advantages such as better drug solubilization, better stabilization, specific localization and controlled release. Hereafter the design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates are reviewed. An overview of HA-paclitaxel combinations is also given.
Collapse
Affiliation(s)
- Francesca Leonelli
- Dipartimento di Chimica and Istituto di Chimica Biomolecolare del CNR, Sezione di Roma, Università degli Studi di Roma La Sapienza, P.le Aldo Moro 5, BOX n. 34 ROMA 62, I-00185 Roma, Italy.
| | | | | | | |
Collapse
|
130
|
Shimoda K, Hamada H, Hamada H. Chemo-enzymatic synthesis of ester-linked taxol–oligosaccharide conjugates as potential prodrugs. Tetrahedron Lett 2008. [DOI: 10.1016/j.tetlet.2007.11.156] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
131
|
Papas S, Akoumianaki T, Kalogiros C, Hadjiarapoglou L, Theodoropoulos PA, Tsikaris V. Synthesis and antitumor activity of peptide-paclitaxel conjugates. J Pept Sci 2007; 13:662-71. [PMID: 17787026 DOI: 10.1002/psc.899] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Paclitaxel (Pac) is the most important anticancer drug used mainly in treatment of breast, lung, and ovarian cancer and is being investigated for use as a single agent for treatment of lung cancer, advanced head and neck cancers, and adenocarcinomas of the upper gastrointestinal tract. In this work, we present the synthesis of five 2'-paclitaxel-substituted analogs in which paclitaxel was covalently bound to peptides or as multiple copies to synthetic carriers. Ac-Cys(CH(2)CO-2'-Pac)-Arg-Gly-Asp-Arg-NH(2), Folyl-Cys(CH(2)CO-2'-Pac)-Arg-Gly-Asp-Ser-NH(2), Ac-[Lys-Aib-Cys(CH(2)CO-2'-Pac)](2)-NH(2), Ac-[Lys-Aib-Cys(CH(2)CO-2'-Pac)](3)-NH(2) and Ac-[Lys-Aib-Cys(CH(2)CO-2'-Pac)](4)-NH(2) were synthesized using 2'-halogeno-acetylated paclitaxel derivatives. Paclitaxel conjugates showed greater solubility in water than paclitaxel and inhibited the proliferation of human breast, prostate, and cervical cancer cell lines. Although all synthesized compounds had an antiproliferative activity, the Ac-[Lys-Aib-Cys(CH(2)CO-2'-Pac)](4)-NH(2) derivative showed improved biological activity in comparison with paclitaxel in cervical and prostate human cancer cells.
Collapse
Affiliation(s)
- Serafim Papas
- Department of Chemistry, University of Ioannina, GR-45110 Ioannina, Greece
| | | | | | | | | | | |
Collapse
|
132
|
Ganesh T. Improved biochemical strategies for targeted delivery of taxoids. Bioorg Med Chem 2007; 15:3597-623. [PMID: 17419065 PMCID: PMC2374751 DOI: 10.1016/j.bmc.2007.03.041] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2006] [Revised: 03/13/2007] [Accepted: 03/14/2007] [Indexed: 12/21/2022]
Abstract
Paclitaxel (Taxol) and docetaxel (Taxotere) are very important anti-tumor drugs in clinical use for cancer. However, their clinical utility is limited due to systemic toxicity, low solubility and inactivity against drug resistant tumors. To improve chemotherapeutic levels of these drugs, it would be highly desirable to design strategies which bypass the above limitations. In this respect various prodrug and drug targeting strategies have been envisioned either to improve oral bioavailability or tumor specific delivery of taxoids. Abnormal properties of cancer cells with respect to normal cells have guided in designing of these protocols. This review article records the designed biochemical strategies and their biological efficacies as potential taxoid chemotherapeutics.
Collapse
Affiliation(s)
- Thota Ganesh
- Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, GA 30322, USA.
| |
Collapse
|
133
|
Kumar SK, Williams SA, Isaacs JT, Denmeade SR, Khan SR. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorg Med Chem 2007; 15:4973-84. [PMID: 17502149 DOI: 10.1016/j.bmc.2007.04.029] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2007] [Revised: 04/13/2007] [Accepted: 04/18/2007] [Indexed: 11/16/2022]
Abstract
Four novel water-soluble peptide-paclitaxel conjugates were designed and synthesized as prostate-specific antigen (PSA)-activated prodrugs for prostate cancer therapy. These prodrugs were composed of a peptide, HSSKLQ or SSKYQ, each of which is selectively cleavable by PSA; a self-immolative linker, either para-aminobenzyl alcohol (PABS) or ethylene diamine (EDA); and the parent drug, paclitaxel. Introduction of a PABA or EDA linker between the peptide and paclitaxel in prodrugs 2-5 resulted in products with an increased rate of hydrolysis by PSA. The stability of prodrugs 2 and 3, with the PABA linker, was poor in the serum-containing medium because of the weak carbonate bond between the PABA and paclitaxel; however, this disadvantage was overcome by introducing a carbamate bond using an EDA linker in prodrugs 4 and 5. Thus, the incorporation of an EDA linker increased both the stability and PSA-mediated activation of these prodrugs. The cytotoxicity of each prodrug, as compared to paclitaxel, was determined against a variety of cell lines, including the PSA-secreting CWR22Rv1 prostate cancer cell line. The EDA-derived prodrug of paclitaxel 5 was stable and capable of being efficiently converted to an active drug that killed cells specifically in the presence of PSA, suggesting that this prodrug and similarly designed PSA-cleavable prodrugs may have potential as prostate cancer-specific therapeutic agents.
Collapse
Affiliation(s)
- Srinivas K Kumar
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
| | | | | | | | | |
Collapse
|
134
|
|